<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bio-rad Laboratories Inc — News on 6ix</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc</link>
<description>Latest news and press releases for Bio-rad Laboratories Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 20:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bio-rad-laboratories-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354d4f78dffbe2df0e5e4c.webp</url>
<title>Bio-rad Laboratories Inc</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc</link>
</image>
<item>
<title>Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-to-report-first-quarter-2026-financial-results-on-thursday-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-to-report-first-quarter-2026-financial-results-on-thursday-april-30-2026</guid>
<pubDate>Thu, 16 Apr 2026 20:15:00 GMT</pubDate>
<description>HERCULES, Calif., April 16, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on Thursday, April 30, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.</description>
</item>
<item>
<title>Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-reports-fourth-quarter-211500076</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-reports-fourth-quarter-211500076</guid>
<pubDate>Thu, 12 Feb 2026 21:15:00 GMT</pubDate>
<description>HERCULES, Calif., February 12, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025.</description>
</item>
<item>
<title>Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-report-fourth-quarter-133000801</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-report-fourth-quarter-133000801</guid>
<pubDate>Thu, 29 Jan 2026 13:30:00 GMT</pubDate>
<description>HERCULES, Calif., January 29, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.</description>
</item>
<item>
<title>Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-management-host-investor-134500291</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-management-host-investor-134500291</guid>
<pubDate>Tue, 06 Jan 2026 13:45:00 GMT</pubDate>
<description>HERCULES, Calif., January 06, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, January 12-15, 2026.</description>
</item>
<item>
<title>Bio-Rad Reports Third-Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-reports-third-quarter-201500121</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-reports-third-quarter-201500121</guid>
<pubDate>Wed, 29 Oct 2025 20:15:00 GMT</pubDate>
<description>HERCULES, Calif., October 29, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/biodesix-announces-expanded-bio-rad-laboratories-partnership-agreement-to-develop-droplet-digitaltm-pcr-high-complexity-assays</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/biodesix-announces-expanded-bio-rad-laboratories-partnership-agreement-to-develop-droplet-digitaltm-pcr-high-complexity-assays</guid>
<pubDate>Wed, 22 Oct 2025 10:17:00 GMT</pubDate>
<description>Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testingLOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic</description>
</item>
<item>
<title>Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-report-third-quarter-213000791</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-report-third-quarter-213000791</guid>
<pubDate>Thu, 16 Oct 2025 21:30:00 GMT</pubDate>
<description>HERCULES, Calif., October 16, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.</description>
</item>
<item>
<title>Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-laboratories-inc-co-000000904</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-laboratories-inc-co-000000904</guid>
<pubDate>Tue, 30 Sep 2025 00:00:00 GMT</pubDate>
<description>HERCULES, Calif., September 30, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Alice N. Schwartz, Bio-Rad’s co-founder and Director Emeritus, passed away on September 25, 2025, at the age of 99.</description>
</item>
<item>
<title>Bio-Rad's Management to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rads-management-participate-upcoming-130000834</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rads-management-participate-upcoming-130000834</guid>
<pubDate>Mon, 25 Aug 2025 13:00:00 GMT</pubDate>
<description>HERCULES, Calif., August 25, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the company’s executive leadership team will participate in the following upcoming investor conferences:</description>
</item>
<item>
<title>Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-host-droplet-digital-130000276</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-host-droplet-digital-130000276</guid>
<pubDate>Fri, 01 Aug 2025 13:00:00 GMT</pubDate>
<description>HERCULES, Calif., August 01, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company’s management will host an informational webinar on Bio-Rad’s Droplet Digital™ PCR (ddPCR™) product portfolio on Tuesday, August 26, 2025, at 10:00 AM Pacific Time (1:00 PM Eastern Time). The event will include a presentation followed by a Q&A session with analysts hosted by Bio-Rad’s President and Chief O</description>
</item>
<item>
<title>Bio-Rad Reports Second-Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-reports-second-quarter-201500268</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-reports-second-quarter-201500268</guid>
<pubDate>Thu, 31 Jul 2025 20:15:00 GMT</pubDate>
<description>HERCULES, Calif., July 31, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-appoints-rajat-mehta-201500823</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-appoints-rajat-mehta-201500823</guid>
<pubDate>Mon, 28 Jul 2025 20:15:00 GMT</pubDate>
<description>HERCULES, Calif., July 28, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company.</description>
</item>
<item>
<title>Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-report-second-quarter-201500439</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-report-second-quarter-201500439</guid>
<pubDate>Thu, 17 Jul 2025 20:15:00 GMT</pubDate>
<description>HERCULES, Calif., July 17, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2025 on Thursday, July 31, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.</description>
</item>
<item>
<title>Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-expands-droplet-digital-130000694</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-expands-droplet-digital-130000694</guid>
<pubDate>Mon, 07 Jul 2025 13:00:00 GMT</pubDate>
<description>HERCULES, Calif., July 07, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.</description>
</item>
<item>
<title>Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-management-host-investor-203000997</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-management-host-investor-203000997</guid>
<pubDate>Thu, 29 May 2025 20:30:00 GMT</pubDate>
<description>HERCULES, Calif., May 29, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025.</description>
</item>
<item>
<title>Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rads-management-participate-fireside-203000335</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rads-management-participate-fireside-203000335</guid>
<pubDate>Mon, 12 May 2025 20:30:00 GMT</pubDate>
<description>HERCULES, Calif., May 12, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time).</description>
</item>
<item>
<title>Bio-Rad Reports First-Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-reports-first-quarter-201500491</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-reports-first-quarter-201500491</guid>
<pubDate>Thu, 01 May 2025 20:15:00 GMT</pubDate>
<description>HERCULES, Calif., May 01, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025.</description>
</item>
<item>
<title>Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025</title>
<link>https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-report-first-quarter-201500125</link>
<guid isPermaLink="true">https://6ix.com/company/bio-rad-laboratories-inc/news/bio-rad-report-first-quarter-201500125</guid>
<pubDate>Tue, 15 Apr 2025 20:15:00 GMT</pubDate>
<description>HERCULES, Calif., April 15, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day.</description>
</item>
</channel>
</rss>